Immuron Limited, a biopharmaceutical company, focuses on the research and development of immunomodulatory polyclonal antibodies for the treatment and prevention of various diseases through its oral immunoglobulins platform in Australia and internationally. The company operates through Research and Development, and HyperImmune Products segments. The company markets Travelan for the prevention of travelers' diarrhea. Its lead product candidate IMM-124E is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease. The company is also developing IMM-529, a clinical stage product for clostridium difficile infections. The company has a research and development collaboration agreement with the Walter Reed Army Institute of Research to develop a vaccine for a form of dysentery; and US Naval Medical Research Center to test the reactivity and therapeutic effectiveness of Travelan against Campylobacter and enterotoxigenic escherichia coli. Immuron Limited was founded in 1994 and is headquartered in Carlton, Australia.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone610398245254
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.43 million
Profitability
Miscellaneous
Employees5
OptionableNot Optionable
IMMURON LTD/S (NASDAQ:IMRN) Frequently Asked Questions
What is IMMURON LTD/S's stock symbol?
IMMURON LTD/S trades on the NASDAQ under the ticker symbol "IMRN."
What price target have analysts set for IMRN?
1 brokers have issued 12-month target prices for IMMURON LTD/S's shares. Their predictions range from $20.00 to $20.00. On average, they expect IMMURON LTD/S's share price to reach $20.00 in the next twelve months. This suggests a possible upside of 151.4% from the stock's current price. View Analyst Price Targets for IMMURON LTD/S.
What is the consensus analysts' recommendation for IMMURON LTD/S?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IMMURON LTD/S in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for IMMURON LTD/S.
What are Wall Street analysts saying about IMMURON LTD/S stock?
Here are some recent quotes from research analysts about IMMURON LTD/S stock:
- 1. HC Wainwright analysts commented, "Valuation, risks and uncertainties. We have valued Immuron using a sum-of-the-parts approach. IMM-124E has a risk-adjusted net present value (rNPV) of $30M, based on a discount rate of 20% and 20% probability of success (reflecting its focus on an area with a very crowded competitive landscape), while IMM-529 has an rNPV of $36M based on a discount rate of 17.5% and 25% probability of success." (7/25/2018)
- 2. According to Zacks Investment Research, "Immuron Limited is a bio pharmaceutical Microbiome company. It focused on oral immunotherapy using polyclonal antibody products for humans. The company is involved in developing therapeutic products in NASH, ASH and other diseases mediated through gut disbiosis. Immuron Limited is based in Armadale, Australia. " (6/12/2018)
Has IMMURON LTD/S been receiving favorable news coverage?
Press coverage about IMRN stock has trended positive recently, InfoTrie Sentiment reports. The research group rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. IMMURON LTD/S earned a news impact score of 2.3 on InfoTrie's scale. They also gave media stories about the company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the company's share price in the near term.
Who are some of IMMURON LTD/S's key competitors?
Some companies that are related to IMMURON LTD/S include Catalyst Biosciences (CBIO), Apricus Biosciences (APRI), OASMIA PHARMACE/ADR (OASM), ASLAN PHARMACEU/ADR (ASLN), Chimerix (CMRX), Vernalis (VNLPY), vTv Therapeutics (VTVT), Chiasma (CHMA), Evofem Biosciences (EVFM), Zynerba Pharmaceuticals (ZYNE), Cumberland Pharmaceuticals (CPIX), Teligent (TLGT), Entasis Therapeutics (ETTX), Pharmaxis (PXSLY) and Iterum Therapeutics (ITRM).
Who are IMMURON LTD/S's key executives?
IMMURON LTD/S's management team includes the folowing people:
- Mr. Peter Anastasiou, Exec. Vice Chairman (Age 59)
- Dr. Jerry Kanellos Ph.D., Chief Operating Officer (Age 58)
- Dr. Gary S. Jacob, Chief Exec. Officer (Age 72)
- Mr. Phillip Allen Hains, CFO & Company Sec. (Age 60)
- Mr. David Lyon, Head of Marketing
When did IMMURON LTD/S IPO?
(IMRN) raised $6 million in an initial public offering (IPO) on Friday, June 9th 2017. The company issued 600,000 shares at $9.99 per share. Joseph Gunnar and Rodman & Renshaw (a unit of H.C. Wainwright & Co.) served as the underwriters for the IPO and WallachBeth Capital was co-manager.
How do I buy shares of IMMURON LTD/S?
Shares of IMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is IMMURON LTD/S's stock price today?
One share of IMRN stock can currently be purchased for approximately $7.9563.
How big of a company is IMMURON LTD/S?
IMMURON LTD/S has a market capitalization of $28.40 million and generates $1.43 million in revenue each year. IMMURON LTD/S employs 5 workers across the globe.
What is IMMURON LTD/S's official website?
How can I contact IMMURON LTD/S?
IMMURON LTD/S's mailing address is 62 LYGON STREET LEVEL 3, CARLTON C3, 3053. The company can be reached via phone at 610398245254 or via email at [email protected]
MarketBeat Community Rating for IMMURON LTD/S (NASDAQ IMRN)
MarketBeat's community ratings are surveys of what our community members think about IMMURON LTD/S and other stocks. Vote "Outperform" if you believe IMRN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMRN will underperform the S&P 500 over the long term. You may vote once every thirty days.
